The Adderall shortage that began in late 2022 was caused by a collision of surging demand, manufacturing delays, and federal production caps that couldn’t adjust fast enough. More than two years later, certain doses remain in limited supply, with some generics not expected to recover until early 2026. The shortage isn’t the result of one single failure but rather several forces hitting at the same time.
Demand Grew Faster Than Supply Could Follow
The biggest driver of the shortage was a sharp increase in the number of people prescribed stimulant medications for ADHD. Diagnoses had been climbing for years, but the pandemic accelerated the trend dramatically. COVID-era stress, remote work struggles, and broader awareness of ADHD in adults all pushed more people toward evaluation and treatment. Globally, ADHD is estimated to affect about 8% of children and 3% of adults, but for decades most of those adults went undiagnosed. That started changing fast.
The numbers from Europe illustrate the scale: in the UK, the share of adults over 25 using ADHD medication jumped from 0.01% in 2010 to roughly 0.20% by 2023, a fifteen- to twenty-fold increase depending on sex. The Netherlands saw its overall ADHD medication use more than double in the same period. The U.S. followed a similar pattern, with adult prescriptions rising steeply during and after the pandemic.
Telehealth Made Prescriptions Easier to Get
During the pandemic, the federal government loosened rules that had previously required an in-person visit before a doctor could prescribe controlled substances like Adderall. Under these temporary telehealth flexibilities, patients could receive a prescription through a video call alone. Companies built entire business models around remote ADHD diagnosis and stimulant prescribing.
The scale was significant. In 2024 alone, more than 7 million prescriptions for controlled medications were written via telehealth without any prior in-person visit. That influx of new prescriptions fed directly into demand for pills that manufacturers weren’t prepared to produce. The federal government has now extended these telehealth rules through 2026 while it works on permanent regulations, meaning this source of demand isn’t going away soon.
Teva’s Manufacturing Problems
On the supply side, the timing couldn’t have been worse. Teva Pharmaceuticals, one of the largest producers of both brand-name Adderall and its generic equivalents, experienced production delays driven by worker shortages. When a dominant manufacturer slows down, the ripple effects are immediate because pharmacies can’t simply switch to another supplier overnight, especially for a controlled substance with strict regulatory requirements around distribution.
Other generic manufacturers couldn’t easily pick up the slack. The economics of generic drug production mean that profit margins are often razor-thin. Federal Trade Commission research has found that low-priced generic drugs carry a significantly higher risk of shortage than higher-priced ones, because manufacturers have less financial cushion to absorb disruptions. Some generic markets are simply too small or too unprofitable to attract enough competitors to ensure a reliable supply. When fees charged by group purchasing organizations and wholesalers eat further into those margins, manufacturers may reduce inventory or stop making certain products entirely.
Federal Production Caps Added a Ceiling
Because amphetamine is a Schedule II controlled substance, the DEA sets an annual cap on how much of it can be manufactured in the United States. These aggregate production quotas are meant to prevent overproduction and diversion, but they also create a hard limit on supply. Even if a manufacturer wanted to ramp up production quickly, it couldn’t exceed its allocated quota without DEA approval.
The DEA’s quota-setting process has historically looked backward at prior-year prescription data to estimate future need, which means it can lag behind sudden jumps in demand. For 2024 and 2025, the quotas for key amphetamine ingredients were held flat: d-amphetamine for sale was set at 21,200 kilograms, d,l-amphetamine at 21,200 kilograms, and lisdexamfetamine (the active ingredient in Vyvanse) at 32,736 kilograms in both years. Flat quotas during a period of rising demand created a bottleneck that manufacturers couldn’t work around on their own.
Middlemen and Distribution Gaps
The path from manufacturer to pharmacy involves layers of intermediaries, including drug wholesalers and group purchasing organizations, whose business practices can worsen shortages. In early 2024, the FTC and HHS jointly launched an investigation into whether these middlemen are contributing to generic drug shortages. The concern centers on a compensation model built around rebates, chargebacks, and administrative fees that may squeeze generic manufacturers and discourage production of low-margin drugs.
These structural problems mean that even when enough medication exists in the overall system, it doesn’t always reach the right pharmacies. Patients in some regions or using certain pharmacy chains have had a much harder time filling prescriptions than others, creating a patchwork of availability that varies by zip code.
What the Shortage Looks Like for Patients
For people who depend on Adderall or its generics to function at work, school, or in daily life, the shortage has been disruptive in ways that go well beyond inconvenience. In a study of 20 people with ADHD interviewed during the shortage, 17 reported a relapse of their ADHD symptoms due to gaps in medication access. Some received only partial prescription fills from their pharmacy. Others were switched to alternative medications that proved less effective.
One participant described going three months without any medication, then cycling through alternatives that didn’t work, followed by more months unmedicated. That kind of disruption can affect job performance, relationships, and mental health, compounding the original condition. The unpredictability has been a defining feature: patients often don’t know whether their prescription will be fillable on any given month, forcing them to call multiple pharmacies or drive long distances to find stock.
Where Things Stand Now
As of early 2026, the shortage has improved for most Adderall strengths but hasn’t fully resolved. The FDA’s drug shortage database shows that most brand-name Adderall tablets are listed as available, with the 7.5 mg dose still in limited supply. The picture for generics is more uneven. Some generic versions from manufacturers like Aurobindo were listed as unavailable through late 2025, with estimated availability pushed to February 2026. Sandoz, another generic supplier, has reported intermittent backorders expected through the first quarter of 2026.
The core problem hasn’t been structurally fixed. Demand for stimulant medications remains high, telehealth prescribing continues at scale, production quotas are flat, and the generic market still runs on thin margins with few new manufacturers entering the space. Until those underlying dynamics shift, the supply of amphetamine-based medications will likely remain tighter than patients and prescribers would like.